Results 91 to 100 of about 12,704,328 (364)
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez +17 more
wiley +1 more source
Homing in on haemoglobinopathies
The Lancet Global Health, 2022 The Lancet Global Health
doaj +1 more source
The Lancet Global Health Commission on financing primary health care: putting people at the centre
Lancet Global Health, 2022 Kara Hanson +23 more
semanticscholar +1 more source
PLoS Medicine, 2004 Why three non-governmental organizations are launching an alternative to the World Health ...
David McCoy +3 more
openaire +5 more sources
Molecular Oncology, EarlyView.This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh +8 more
wiley +1 more source
A novel coronavirus outbreak of global health concern
The Lancet, 2020 Chen Wang, P. Horby, F. Hayden, G. Gao
semanticscholar +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Amplifying the global issue of hearing loss
The Lancet Global Health, 2022 The Lancet Global Health
doaj +1 more source